The Revenue You Are Leaving on the Table
A mass tort case referral generates revenue for referring firms through contractual fee-sharing arrangements that require zero litigation infrastructure and minimal time investment. For general practice and personal injury firms fielding calls about defective drugs, failed medical devices, or toxic exposure, these referrals represent a largely untapped income stream. With several major MDLs approaching settlement resolution in 2026, the window to establish co-counsel relationships and capture that value is closing faster than most firm principals recognize.
This post is about the economics, the mechanics, and the compliance requirements of building a referral strategy that actually pays off, whether you are the firm sending cases out or the firm trying to attract quality co-counsel relationships at scale.
What a Mass Tort Case Referral Actually Is and Why It Belongs in Your Business Model
A mass tort is coordinated litigation involving large numbers of plaintiffs who suffered similar injuries from a common product or conduct, typically a defective drug, a medical device, or an environmental exposure. These cases are not handled the same way a standard personal injury case is. They are almost always centralized in a federal MDL, governed by Plaintiff Steering Committee orders, and resolved through global settlement matrices rather than individual jury verdicts. That structure creates enormous economies of scale for firms that specialize in them, and real inefficiency for firms that do not.
A mass tort case referral is the formal arrangement where a firm that receives or identifies a qualifying claimant transfers that case to a mass tort attorney or specialized firm better equipped to litigate it, in exchange for a percentage of the eventual fee. From a business standpoint, this is pure margin on a case you would otherwise never monetize. The referring attorney does not need to staff up, learn MDL procedure, or carry the case for three to seven years. They send it, they document it properly, they stay in ethical compliance, and they collect when the case resolves.
For firms that run any kind of advertising, even general PI ads, this matters immediately. Call volume for mass tort injuries already exists in your pipeline. The question is whether you are capturing that revenue or walking away from it.
The Numbers: What the Economics of a Mass Tort Case Referral Actually Look Like
Referral fees in mass tort litigation are typically structured as a percentage of the total contingency fee, not a percentage of the gross recovery. Model Rule 1.5(e) and its state equivalents govern the split, and I will get into compliance specifics below. In practice, referring attorneys commonly receive between 25% and 33% of the total attorney fee, though the range runs wider depending on the tort, the MDL, and what work the referring firm agrees to perform.
Here is how that looks in real money. A single Bard PowerPort case, to use a current example, carries an estimated settlement value in a range that could put $50,000 to $150,000 or more in total fees on a single case. A referring firm taking 25% of a 33% contingency fee on a $200,000 gross recovery collects roughly $16,500 for initial intake, proper documentation, and maintaining the client relationship. Do that across 20 cases in a year and you have added $330,000 in revenue without hiring a single MDL litigator.
The timing variable is critical and almost nobody talks about it. MDL bellwether trials, global settlement negotiations, and claims administrator deadlines all affect case value and viability. A case referred into an MDL before the discovery cutoff is worth significantly more than the same case referred after a settlement matrix is locked. Firms that are slow to act on intake calls for active torts are not just losing revenue, they are referring cases at a discount, or in some instances missing the window entirely. If a claimant contacts your firm about a tort where the MDL has already entered a settlement agreement with filing deadlines, you have weeks, sometimes days, to get that case signed and transferred to a qualified mass tort firm.
Cost benchmarks for acquiring those cases through advertising vary by tort. Signed mass tort cases across categories like AFFF, talc, NEC baby formula, and surgical stapler litigation have ranged from $800 to $5,000 per signed case depending on the channel, the tort maturity, and how well the intake process is built. Firms with strong organic intake through their existing client base and referral networks are acquiring cases at close to zero incremental cost. That is the most profitable version of this model.
How to Execute a Mass Tort Case Referral the Right Way
Execution separates firms collecting meaningful referral income from firms that signed a few cases, never heard back, and wrote the whole thing off. Here is what the winning side of this looks like.
First, vet the receiving firm seriously. Brand recognition is not a vetting criterion. Ask for MDL-specific experience, Plaintiff Steering Committee participation history, and references from other referring attorneys. Find out how they communicate with co-counsel during the life of the case. A mass tort attorney who does not return calls from referring firms during the litigation is not a partner you want. Red flags include firms that will not put fee division terms in writing immediately, firms that do not provide case status updates at reasonable intervals, and any firm that discourages you from maintaining contact with your own client.
Second, document everything before the case leaves your office. The written fee-sharing agreement needs to be signed by all attorneys and the client, and it needs to clearly state each lawyer's responsibilities. Do not treat this as a formality. It is your protection if the relationship sours and the basis for your fee at the end of a case that may take five years to resolve.
Third, maintain your client relationship after the referral. This is where most referring attorneys go wrong. The client is still your client. You have ongoing communication obligations. If something changes in the litigation, the client should hear it from you or at least know you are available. Firms that disappear after the referral create bar complaints, not income.
Fourth, build intake systems that capture these cases efficiently. This means training your intake staff to identify mass tort fact patterns, using a screening checklist tied to current active torts, and having a fast path to get that caller to someone who can evaluate the case the same day. Slow intake in mass tort is expensive. Cases are time-sensitive in ways that ordinary PI cases often are not.
Pitfalls and Compliance: What Trips Firms Up
Model Rule 1.5(e) requires three things for a compliant fee division: the client must consent in writing after full disclosure, the fee division must either be proportional to services performed or each attorney must assume joint responsibility, and the total fee must be reasonable. Most states have adopted this structure with minor variations, but a handful have stricter requirements. California, for example, has additional disclosure obligations under Rule 1.5.1. Florida has its own fee agreement rules with specific language requirements. Check your jurisdiction before you sign anything.
TCPA and state-level wiretapping statutes like CIPA matter the moment you start using digital intake tools, SMS follow-ups, or call recording in your intake process. Firms that buy leads from third-party vendors and then call those leads aggressively have been hit with TCPA class actions. This is not theoretical. Compliance here requires documented consent at the point of lead capture, not after the fact.
On the advertising side, inflated cost-per-lead numbers from vendors who are selling the same leads to multiple firms at once is a chronic problem. If your signed case cost is wildly higher than benchmark and your signing rate is low, the issue is usually lead quality, not intake conversion. That is a vendor problem, not something you can fix with better scripts.
How MTAA Supports This Strategy
At Mass Tort Ad Agency, we work exclusively with plaintiff law firms on the advertising and intake side of mass tort acquisition. We have managed over $250 million in Facebook ad spend for more than 600 law firms across more than 100 torts. Our pricing model is transparent: ad spend plus a 15% management fee, nothing buried in margins on your media buy.
For firms building referral pipelines, we handle the front end of that funnel, the campaigns that surface qualified claimants, the intake workflow that gets them signed, and the targeting strategy that matches spend to torts where the MDL timing actually supports investment. We do not take referral fees. We do not share your leads. We run the campaigns, you own the cases.
AI is increasingly part of how we and our clients operate, from automated intake qualification to document summarization for case evaluation. If your firm is exploring how to integrate AI into intake and case management, my book "A Lawyer's Guide to AI" covers the practical side of that for plaintiff firms specifically.
Close: Build the Mass Tort Case Referral Into Your Revenue Strategy Now
The mass tort case referral is not a passive income strategy that works by accident. It requires the right receiving partner, airtight fee agreements, disciplined client communication, and intake systems fast enough to capture cases before MDL deadlines close the door. Firms that build this infrastructure are adding seven-figure revenue from case volume they already have. Firms that ignore it are donating that revenue to someone else. The compliance framework is manageable, the economics are real, and the opportunity in several active torts right now is significant. The time to get the structure right is before you have a pipeline of cases sitting in a spreadsheet with no clear path to monetization.
Ready to Build Your Caseload?
Get a free campaign analysis from Mass Tort Ad Agency.
$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.
Schedule a Free Consultation →Frequently Asked Questions: Mass Tort Case Referral Economics
What are the typical referral fee structures and co-counsel economics when sending mass tort cases to a lead firm?
Referral fees in mass tort cases are typically negotiated as a percentage of the total attorney fee recovered, commonly ranging from 25% to 40% of the lead firm's contingency, depending on the quality of the case and the MDL involved. Some arrangements are structured as true co-counsel agreements where the referring firm retains a formal role and a larger fee split, while others are pure referral arrangements governed by your state bar's fee-sharing rules. Either way, the economics are almost always superior to attempting to work the case in-house without mass tort infrastructure.
What does it cost to acquire a signed mass tort retainer, and how should a firm evaluate whether the acquisition economics pencil out?
Signed case acquisition costs vary significantly by tort, but firms using paid digital advertising can expect to spend anywhere from $500 to over $3,000 per signed retainer depending on the docket, with high-value device and drug cases trending toward the upper end of that range. The key underwriting metric is the expected per-case fee recovery discounted by settlement probability and timeline, and a referral arrangement amplifies margin because the referring firm offloads litigation costs entirely. Firms using a cost-plus intake model, where media spend is passed through at cost with a fixed administrative markup, can often acquire inventory more efficiently than running proprietary ad budgets without dedicated mass tort media expertise.
Is there still meaningful claimant volume available in current MDLs, or are the major dockets already saturated at the intake level?
Several active MDLs, including those involving AFFF firefighting foam, hair relaxer products, and certain CPAP device failures, still have substantial unrepresented claimant populations that have not been reached by plaintiff firms. Saturation is docket-specific and shifts rapidly as settlement announcements accelerate intake competition, so firms evaluating entry need current data on total estimated claimant universe versus filed plaintiff counts. The gap between eligible claimants and represented plaintiffs often remains wide in the middle phases of an MDL, which is precisely when referral economics are most favorable for firms standing up intake operations.
What advertising channels and creative strategies are most effective for generating mass tort leads at the firm level?
Paid search, programmatic display, and meta platforms are the dominant channels for mass tort claimant acquisition, with television and connected TV still delivering volume for firms targeting older demographics associated with specific drug or device injuries. Creative must lead with the product or exposure name rather than legal terminology, and compliance with state bar advertising rules as well as FTC guidelines on claims requires review before any campaign goes live. Firms working with a dedicated mass tort media partner using a cost-plus model gain transparency into actual media spend and avoid the margin markups common in traditional lead generation, which directly improves cost-per-signed-case performance.
What bar compliance and fee-sharing disclosure requirements does a referring firm need to satisfy before monetizing mass tort case referrals?
Model Rule 1.5(e) and its state equivalents require that fee-sharing arrangements between lawyers at different firms be disclosed to the client in writing, that the client consent to the arrangement, and in most jurisdictions that the fee division be proportionate to services rendered or that each attorney assume joint responsibility. Some states have additional mass tort advertising disclosure requirements and prohibit certain referral structures entirely, so a jurisdiction-by-jurisdiction review is necessary before building a systematic referral pipeline. Firms should also confirm that the receiving lead firm carries adequate malpractice coverage and is in good standing in the MDL's governing jurisdiction, as joint responsibility exposure can follow the referring attorney regardless of operational involvement.
